Disability due to ocular complications of diabetes and ways of its prevention
Iskandarova Sh.T., Nabiyev A. M., Djamalova Sh.A., Makhmudova S. M.
Tashkent Pediatric Medical Institute; Tashkent (Uzbekistan)
Introduction. Diabetic retinopathy is one of the leading cause of total vision loss in the working population in developed countries.
The aim studying the structure of disability due the ophthalmic complications of diabetes and the efficacy of using fenofibrate by patients with diabetic retinopathy.
Material and methods. The study consisted of 2 blocks. In the first copies of 347 individual inspection certificates in MLCE’s of Tashkent for 10 years were obtained. Second — included examination of 56 patients (112 eyes) suffering from type II diabetes. Patients were divided into 2 groups — control and basic, patients of the basic group was administered fenofibrate 145 mg 1 time per day.
Results and discussion. In more than 94 % of those surveyed due to diabetic retinopathy, Ist (66 %) and IInd (29 %) degree of disability was revealed, which indicates severe disability of patients. In the control group, two patients with IIIrd group of disability and three patients with II group, due to worsening state has changed groups on the IInd and IIIrd respectively. In the main group — two patients with III-rd group and one with IInd group changed to the IInd and Ist.
Conclusions. Fenofibrate slows the progression of diabetic retinopathy, which allows it to be recommended as a therapeutic and prophylactic therapy.
Key words: disability, diabetic retinopathy, pharmacological prevention.
Balashevich LI, Izmailov AS. Diabetic ophthalmopathy. SPb.: Chelovek; 2012. 396 p.
Doslina EV. Rehabilitation care for patients with diabetic neuropathy. Mediko-sotsialnaia ekspertiza I reabilitatsiia. Moscow. 2012;1: 16–8. In Russian.
Ismoilov SI. Endocrinology Service in Uzbekistan. Organizatsiia I upravleniie zdravookhraneniiem. Tashkent. 2012;7:42–53. In Russian.
Kamilov KhM, Ismailov SI, Akbarov ZS et al. Diabetic retinopathy. Training and guidelines. Tashkent; 2008. 16 p.
Kitch AK, Mitchell P, Sammanen PA et al. On behalf of the authors of the FIELD study. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (research FIELD): a randomized controlled trial. Obzory klinicheskoi kardiologii. 2009;20:5–12. In Russian.
Colwell JA. Diabetes. New in the treatment and prevention. M: BINOM; 2010. 288 p.
World Health Statistics. 2010: World Health organization. Copenhagen; 2010. 177 p.
Skorobogatova ES. Disability-free as a result of diabetes. M.: Meditsina; 2003. 208 p.
Shagazatova BKh. Diabetes: the state of health and social care and improving the foundations of therapeutic and preventive measures: thesis for Doc. of Med. Sc. Tashkent. 265 p.
Chew EY, Ambrosius WN, Davis MD, Danis RP, Gangaputra S et al. ACCORD Study Group; ACCORD Eye Study Group, Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report No 9. Ophthalmology. 1991;98:766–785.
Kimoto K, Kuboto T. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol. 2012;3:177–83.
Klein BE, Moss SE, Klein R et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmol. 1991;98(8):1261–1265.
Mitchell P, Bandello F, Schmidt-Erfurth U et al. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615–625.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabet. Res.Clin. Pract. 2010;87(1):4–14.